Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

34.43

-0.03 (0.09%)

as of Aug 4, 2026, 8:00:00 pm Market Open.

70 watching

Investor Insights

Aug 4, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) has garnered mixed reviews from various experts, reflecting a dynamic yet cautious outlook on its performance. In recent months, the stock has significantly appreciated, showing a 264% increase since early 2023 under the leadership of its current CEO. Despite this positive trajectory, experts express concerns regarding the erosion of prices in the GLP market as more generics come into play, which could impact Teva's profitability. While it has exhibited strong momentum and accumulated growth since breaking the $21 mark in September, there's skepticism about its level of innovation in an increasingly competitive pharmaceutical landscape. Analysts project a bullish target price of $34.50, underlining potential optimism despite the caveats presented in the commentary.

Consensus

Mixed

Valuation

Fair Value

Similar

Novartis, NVS

BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

DON'T BUY

Prefers others.

BUY

One of the world's largest genetic drug manufactor company. The stock has dropped in the last few weeks. This is a good opportunity to buy stocks.

TOP PICK

Wonderful company. Not overvalued.

BUY ON WEAKNESS

Generic drugs is a great sector. This one is the leader. Accumulate on a gradual basis.

HOLD

Generic drug space is a good place to be. A little high now.

TOP PICK

Generic drugs have done very well. Have increased their margins regularily. Steadily moving up.

BUY

Good growth trend. Good products. May drop in the near term.

Wealthica Track your Stocks in your Watch List

TOP PICK

Likes the generic drug sector.

PAST TOP PICK

(Was a top pick on Aug 23. Up 1%) Still likes. Likess the generic sector in drugs.

TOP PICK

Stable revenue stream and earnings record. Likes the generic drug sector.

PAST TOP PICK

(Was a top pick on Mar 15. Up 19%.) Still likes.

PAST TOP PICK

(Was a top pick on June 21. Up 7.1%) Good long term story.

TOP PICK

Over 50 new drugs waiting approval. Cheap.

TOP PICK

Global. Good acquisitions. Because it is based in Israel, price has dropped inordinately.

Showing 256 to 270 of 276 entries

Most Recent Experts

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

The Monthly Gems by Allan Tong

Stockchase

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)